Becton, Dickinson and Company (NYSE:BDX) is one of the top stocks that Grok recommended. On July 31, Becton, Dickinson and ...

Becton, Dickinson (BDX) stock gains as the company boosts fiscal 2025 earnings outlook after better than expected Q3 results.

Becton Dickinson shares surged over 8% in premarket trading on Thursday after the medical technology company reported ...

Shares of Becton Dickinson & Co. rose 8.86% to $187.68 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.08% to 6,340.00 and Dow ...

Q3 2025 Management View CEO Thomas E. Polen reported sequential improvement in growth, stating "We accelerated commercial initiatives and increased our organic growth trajectory through market ...

Becton Dickinson beat Q3 earnings and revenue estimates, raised its FY25 EPS outlook, and saw strong growth in its medical ...

Detailed price information for Becton Dickinson and Company (BDX-N) from The Globe and Mail including charting and trades.

Becton Dickinson & Co. closed 29.80% below its 52-week high of $251.99, which the company reached on February 3rd.

The stock's rise snapped a five-day losing streak.

Becton Dickinson raised its forecast for annual profit on Thursday, after beating Wall Street estimates for third-quarter profit and sales on strong demand for its drug-delivery devices.

Waters said it reached a deal to buy the Biosciences & Diagnostic Solutions business of Becton Dickinson for around $17.5 ...

Lab equipment maker Waters Corp on Monday said it will buy a bioscience and diagnostics unit spun off from medtech provider Becton Dickinson in a stock-and-cash transaction valued at $17.5 billion, ...